Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FL1V7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $98,899
Award facts
- Contract value 100% obligated
- $98,898.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 27, 2025, by the Defense Logistics Agency (DLA) for the supply of Entyvio 300 mg vials. This firm fixed-price delivery order, valued at $98.9K, is scheduled for completion by September 18, 2025, with performance taking place in Park Ridge, Illinois. The award carries no set-aside designation, indicating the contractor competed on an unrestricted basis despite its small business status.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500M indefinite delivery vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products to support military health facilities worldwide. Entyvio (vedolizumab), a biologic injectable medication used in the treatment of inflammatory bowel disease, represents one of the specialized pharmaceutical products within the contractor's extensive portfolio of branded and generic prescription drugs, biologics, and medical consumables. The DLA's pharmaceutical supply chain relies on established contractors like DMS Pharmaceutical Group to ensure consistent availability of critical medications to Department of Defense healthcare sites globally.
Quick answers
Who was awarded contract SPE2DB25FL1V7?
SPE2DB25FL1V7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 27, 2025.
How much is contract SPE2DB25FL1V7 worth?
The government has obligated $98,899 on SPE2DB25FL1V7.
Is contract SPE2DB25FL1V7 an order under another contract?
Yes. SPE2DB25FL1V7 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB25FL1V7 competed?
The extent of competition for SPE2DB25FL1V7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award